The biotech industry in Norway challenges and opportunities. Torfinn Hansen, Pfizer AS

Transkript

1 The biotech industry in Norway challenges and opportunities Torfinn Hansen, Pfizer AS

2 A new strategy for biotech signed by 6 Governmental Ministries!

3 Biopharma production - needs? Stable workforce Pharmaceutical competence Clean air and water Distance to market minor importance Excellent for decentralized localization

4

5 Halden Plant supplies Zyvoxid to the world!

6 Suksessbedrift vokser videre Fresenius Kabi på Remmen går så det suser. Bedriften bygger ut. Snart har den 500 ansatte. AV KÅRE RENNESTRAUM Publisert: ( ) - Vi forsvarer vår posisjon med høyeffektiv produksjon og gode medarbeidere. Videre har vi vår styrke i stabile leveranser til våre kunder. Markedet kan rett og slett stole på oss sier fabrikksjef Sten H. Strandberg. Bedriften tapper og pakker en rekke flytende legemidler beregnet for intravenøs bruk. 500 employees 500 ansatte - Vi nærmer oss 500 ansatte og snart er vi over det tallet. Vi trenger nye medarbeidere bl.a. til en ny produksjonslinje, sier fabrikksjefen. Med 500 ansatte er Fresenius Kabi den tredje største industribedriften i Halden etter Saugbrugs og Nexans, - Vi er stolte over å kunne tilby arbeid til så mange. Store deler av produksjonen går døgnet rundt året rundt, og da trenger vi folk, sier Strandberg. -Interessen for jobb hos oss er stor. Til enhver tid har vi en stor bunke med søknader om jobb. Vi har sluttet å avertere når vi skal ansette flere operatører. Vi har nok søknader allerede. 70% females Mange kvinner - Vi er Haldens største industriarbeidsplass for kvinner. Med så mange kvinner blir det gjerne en del svangerskapspermisjoner. Det igjen gjør at vi hele tiden trenger nye folk inn i bedriften, sier fabrikksjefen. Bedriften bruker nå 30 millioner kroner på en ny produksjonslinje som erstatter en eldre. -Når denne linjen kommer i gang ut på nyåret, vil den ha en kapasitet på 14 millioner enheter i året. Markedsverdien av produksjonen på denne linja er hele 7,5 milliarder kroner. Vår andel ligger på ca 200 millioner kroner i året, sier fabrikksjef. En fornøyd gjeng ved den nye tappelinjen. Den vil tilføre bedriften 200 mill i omsetning. Fra venstre: Produksjonssjefavdelingsleder Robert Saintenoy, prosjektleder Birgit Aanby, ersonalsjef Anne Øwre og fabrikksjef Sten Strandberg. Foto: Kåre Rennestraum Stort overskudd Årsomsetningen er på 700 Margin/Revenue: millioner kroner og overskuddet på hele 170/700 millioner kroner Mill i NOK Det er få, om noen, større bedriften som kan måle seg med Fresenius Kabi når det gjelder overskudd i forhold til omsetning. Nesten 25 prosent av omsetningen er overskudd som sendes til konsernet i Tyskland. -Vi forventer omtrent samme omsetning og overskudd for inneværende år og ser heller ingen mørke skyver på himmelen som skulle tilse noen endring av bedriftens kraftige overskudd i 2010, sier Strandberg. Bygger ut Bedriften får nå bygd et nytt lager som skal betjenes av roboter førerløse trucker som er programmert til jobben. Når det nye lageret er tatt i bruk planlegges en ny utvidelse så snart bedriften får tilgang på mer areal. Nybygget skal erstatte et eldre lagerbygg som igjen skal bygges om til produksjon. Fresenius Kabi startet med bedriften Travenol i Siden skiftet bedriften navn og eier flere ganger før det tyske storkonsernet Fresenius med ansatte overtok. Denne produksjonslinjen ved Fresenius Kabi skal byttes ut med ny teknologi. Halden Arbeiderblad,

7

8

9

10

11 Dagens Næringsliv, 24. desember 2010

12 Dagens Næringsliv, 24. desember 2010

13 He says that Lytix, given that the highly promising research will succeed, sooner or later will depend on industrial partnerships. - The whole system has become so, that the large corporations have become product developers, marketers and manufacturers of drugs and they are buying new projects in the early development face. To get into such a position, we could be attractive with good initial results. The next goal is to get into good deals so we can industrialize some of it locally, and not give away everything. Dagens Næringsliv, 24. desember 2010

14 Algeta get into an agreement with Bayer worth 5 Billion NOK!

15 Clavis has made an agreement worth Billions of NOK! Legemiddelselskapet Clavis Pharma inngår en strategisk samarbeidsavtale for Amerika og Europa til en anslått verdi på over 2,1 milliarder kroner knyttet til kreftlegemiddelet CP Avtalen omfatter videre utvikling og kommersialisering av legemiddelet, som nå testes i kliniske fase II-undersøkelser. - En veldig god avtale - Dette er en veldig god avtale for oss. Vi har fått en partner som vil investere betydelige midler for å utvikle legemiddelet vårt, sier administrerende direktør Geir Christian Melen i Clavis Pharma til

16 Our primary conclusion is that there is untapped potential related to translating the ideas, technologies, and capabilities coming out of Norwegian biopharma research into more commercial value creation. In short, Norway has a strong research platform that is not being fully commercialized. This presents an opportunity.

17 INNOVATION UNION SCOREBOARD 2010, The Innovation Union's performance scoreboard for Research and Innovation, 1 February 2011, Prepared by the Maastricht Economic and social Research and training centre on Innovation and Technology (UNU-MERIT) with the contribution of DG JRC G3 of the European Commission.

18 COUNTRY PROFILES INNOVATION UNION SCOREBOARD 2010, The Innovation Union's performance scoreboard for Research and Innovation, 1 February 2011, Prepared by the Maastricht Economic and social Research and training centre on Innovation and Technology (UNU-MERIT) with the contribution of DG JRC G3 of the European Commission.

19 Summary The general conclusion of the evaluation of FORNY is that despite the positive additionality and the successful targeting of high technology commercialisation projects, the overall results of FORNY are not very impressive. It should be mentioned that comparisons are extremely difficult and there may be indirect results and a positive dynamics taking place. Still, we worry about the lack of firms that have grown large and the generally poor growth rate compared to international cases.

20 ANP: 2010:748 ISBN: Nordic Council of Ministers Ved Stranden 18 DK-1061 Copenhagen K

21 Norway Norway is the best-performing Nordic country on bankruptcy regulation and access to finance. Norway also has low import and export burdens. Nevertheless, Norway provides the weakest overall entrepreneurship framework conditions among the Nordic countries. This is also reflected in low entrepreneurship performance both on start-up and firm growth. There is room for improvement in Norwegian labour market regulation and entrepreneurial culture.

22 Finland Finland has a strong entrepreneurship performance and the best overall framework conditions for entrepreneurship in the Nordic region. Finland has particularly strong entrepreneurial capabilities. On the other hand, Finland lacks highly-skilled foreign entrepreneurs, and a rigid Finnish labour market regulation has a negative impact on the possibilities for hiring and firing new employees in firms. Finland also lacks a strong entrepreneurial culture.

23 Everything is connected with everything! * Norway is an outlier in drug policy! *Gro Harlem Brundtland

24 Norway is a divergent within the pharma area Invest among the most in the world in health care, but among the lowest in drugs Illogical system for price setting price level at the bottom in Europe Weaknesses in the handling of the patent system Biosimilars intended to be included in the drug exchange system Pediatric extension is not yet adapted

25 Lowest possible prices for drugs

26 Price determinations The price of a prescription-only medication in Norway is set as the mean of the three lowest market prices of the product in a selection of countries. The countries which are included in the price comparison group are: Sweden, Finland, Denmark, Germany, UK, The Netherlands, Austria, Belgium and Ireland.

27 Price determinations The price of a prescription-only medication in Norway is set as the mean of the three lowest market prices of the product in a selection of..mean of the countries. three lowest.. The countries which are included in the price comparison group are: Sweden, Finland, Denmark, Germany, UK, The Netherlands, Austria, Belgium and Ireland.

28 Low drug prices may initially means cost savings, but may also reduce incentives for innovation and introduction of drugs in national markets. The economic impact is highly uncertain. Professor Kurt Brekke, Paraplyen NHH,

29

30 I think it is a clear signal to the industry that we are keen to have the best possible environment for research and development of new medicines, but also that we will have the medication at the correct price. Sundhetsminister Jakob Axel Nielsen

31 The future gold mine?

32 - Very interesting in tomorrow's medicine! Within a few years, there successfully is built up a unique team of researchers affiliated with the university and several institutions in Tromsø. Here are collected a number of species from the icy seas, often deep, and these contain substances that the world's biopharma industry would like to use. There are values in fish and marine life that only the imagination limits. Minister of Fisheries and Coastal Affairs Lisbeth Berg-Hansen Large export value! The Minister seems there is an interesting thought that some few molecules can have bigger value than a whole year export of seafood. Last year Norway exported for about 45 billion NOK. A small mushrooms were in the 60s found on Hardangervidda, and substances of this forms the basis for a medicine that makes the new organs accepted after transplantation. The Swiss company that developed the fungus, now sells medicine for over 10 billion NOK each year. [ :31:27]

33 The government has a strategy for marine bioprospecting. The aim is to promote wealth creation and economic development nationally, with particular focus in the north region. Results from bioprospecting can be applied in a number of areas, such as new drugs, food, feed and biofuel.

34 The Trade and Industry Ministry's budget for 2012, includes 25 million NOK for industrial research and commercialization relating to marine bioprospecting.

35 Document 8 proposal in Parliament Parliament March 29 th, 2011

36 Document 8 proposal in Parliament A need for a more pro-active attitude towards the Pharma industry Faster implementation of experimental medication and treatment is a success factor in biomedicine Norway an outlier in the Pharma area a need for implementation of internationally competing conditions for the industry A need for a new Policy Document concerning drug policy Norway need a faster implementation of new and innovative drugs in order to secure research and development, and better treatment options for patients Parliament March 29 th, 2011

37 The new facility is the largest plant for commercial production of biotechnology drugs in Sweden, and one of the largest industrial investment with its 1.5 billion SEK. The new plant will account for Pfizer's global production of growth hormone Genotropin and Fragmin.

38 Berlingske Tidende Januar 4 th, 2011

39 With the agreement, Santaris Pharma receives 14 million USD, equivalent to about 80 million DAK in cash for Pfizer s access to Santaris Pharma's so-called LNA technology to develop RNA-targeted drugs, which can become the basis for a new generation of innovative drugs from the medical and biotech industry. Santaris has also access to milestone payments up to 600 million USD, about 3.4 billion DAK, and license income of the global sales of finished pharmaceuticals. Berlingske Tidende Januar 4 th, 2011

40 Summary Norway Excellent base of ideas opportunities for development Good climate for fundings Spesific opportunities for blue biotech Public has a positive attitude to biotech National strategy established strong government support Lack of understanding for connections drug/industry policy Denmark/Sweden more attractive for partnership Culture barriers academia/government/industry

41 Great opportunities for more plants!